Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram for depression in patients with systolic heart failure
IRCT20230510058142N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) and heart failure with reduced ejection fraction (HFrEF) comparing Escitalopram with Placebo (2 arms). Primary endpoints: Quality of life and Hospitalization rate. Started May 2023; status: completed.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on IRCT20230510058142N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230510058142N1.